Granules India Limited · NSE:GRANULES
Granules India — Q3 FY2025 Earnings Presentation
23 slides from Granules India's earnings presentation, Jan 24, 2025
Slide 1: Cover letter to stock exchanges: Presentation to Analysts/Investors
Gg GRANULES REGISTERED OFFICE GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad - 500 081, Telangana, India. Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com CIN: L24110TG1991PLC012471 Date: January 24, 2025 To, National Stock Exchan
Slide 2: Earnings Presentation – Q3FY25
Granules India Limited Earnings Presentation – Q3FY25 24th January 2025 Embracing Change. Shaping Tomorrow. 1
Slide 3: Safe Harbour Statement
Safe Harbour Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendatio
Slide 4: Key business updates for Q3 FY25
Key business updates for Q3 FY 25 ▪ Gagillapur facility Inspection: The Company voluntarily paused the production in the Gagillapur plant in Sep-24 for a risk assessment on account of the US FDA observations. Subsequently in October, the production resumed in a staggered manner. ▪ Gross Margins: Sus
Slide 5: Quarterly Performance
Quarterly Performance Q3 FY 25 Earnings Presentation – Q3 FY 25 © 2024 Granules India Limited 4
Slide 6: Q3FY25 P&L: Y-o-Y Performance
Q3FY25 P&L: Y-o-Y Performance (In ₹ Mn) Q3 FY25 Q3 FY24 Y-o-Y Gr% Remarks on Y-o-Y performance YoY growth in FD has been offset by the continued Revenue 11,377 11,556 -2% decline in API/PFI due to lower demand and persistent price erosion Gross Margin 7,020 6,583 Achieved better margins with a highe
Slide 7: Q3FY25 P&L: Q-o-Q Performance
Q3FY25 P&L: Q-o-Q Performance (In ₹ Mn) Q3 FY25 Q2 FY25 Q-o-Q Gr% Remarks on Q-o-Q performance Voluntarily paused production in the Gagillapur plant in Revenue 11,377 18% Sep -24 for a risk assessment on account of the US FDA 9,666 observations. Subsequently in October, the production resumed in a s
Slide 8: Revenue split by Segments and Market
Q2FY25 : Revenue spilt by Segments and Market (In ₹ Mn) Division wise share Region wise share Q3 FY24 3% 5% 3% Q2 FY25 Q3 FY25 5% 4% 5% 6% 2% 6% 10% 9% 20% ROW 15% 8% 12% LATAM 15% 12% India 19% Europe 79% 77% 66% North America 66% 77% 76% FD API PFI Q3 FY24 Q2 FY25 Q3 FY25 FD API PFI FD API PFI Q3
Slide 9: Q3FY25 Cashflow and Ratios: Q-o-Q
Q3FY25 Cashflow and Ratios : Q-o-Q (In ₹ Mn) Q3 Q2 Q3 Q2 Q3 Q2 FY25 FY25 FY25 FY25 FY25 FY25 Fixed Net debt/ ROCE% 16.4% 16.9% asset turn 1.56 1.56 EBITDA 0.90x 0.86x Slight decrease in ROCE% due to additions in capex Maintained Maintained ROCE = Annualised EBIT / Average capital employed Capital em
Slide 10: Historical Performance
Historical Performance Earnings Presentation – Q3 FY 25 © 2024 Granules India Limited 9
Slide 11: Sales and profitability: Last 6 quarters historical performance
Sales and profitability : Last 6 quarters historical performance (In ₹ Mn) Sales Gross Margin and GM% 11,895 11,758 11,799 7,062 6,954 7,020 11,556 11,377 6,583 5,994 6,144 9,666 60.1% 61.7% 57.0% 58.9% 62.0% 51.7% Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 E
Slide 12: Cashflow and Ratios: Last 6 quarters historical performance
Cashflow and Ratios: Last 6 quarters historical performance (In ₹ Mn) ROCE% Asset turns Net debt and Net debt/EBITDA 1.75 1.78 1.77 9,895 1.74 9,285 19.6% 8,421 8,289 16.9% 7,941 7,973 16.5% 16.4% 15.3% 1.56 1.56 1.41 1.16 12.8% 0.98 0.86 0.90 0.77 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q2FY24 Q3
Slide 13: Sales and profitability: Last 5 years historical performance
Sales and profitability : Last 5 years historical performance (In ₹ Mn) Sales Gross Margin and GM% EBITDA and EBITDA % PAT and PAT % Earnings Presentation – Q3 FY 25 © 2024 Granules India Limited 12 12
Slide 14: Cashflow and Ratios: Last 5 years historical performance
Cashflow and Ratios: Last 5 years historical performance (In ₹ Mn) ROCE% Asset turns Net debt and Net debt/EBITDA CCC days Operating Cash flow Capex Earnings Presentation – Q3 FY 25 © 2024 Granules India Limited 13 13
Slide 15: Granules at a glance
Granules at a glance Earnings Presentation – Q3 FY 25 © 2024 Granules India Limited 14
Slide 16: Granules Purpose, Vision & Values
Granules Purpose, Vision & Values Earnings Presentation – Q3 FY 25 © 2024 Granules India Limited 15
Slide 17: An Illustrious Journey Spanning Four Decades
An Illustrious Journey Spanning Four Decades Building A World Class, Vertically Integrated Pharmaceutical Manufacturing Platform From being a paracetamol API manufacturing facility to a multi-faceted global pharmaceutical company, we have consistently achieved manufacturing success, set new standard
Slide 18: Manufacturing Network & Capacity
Manufacturing Network & Capacity FD: 2.5 Bn dosage (Phase I) FD: 7.5 Bn dosage (upcoming Phase II) Earnings Presentation – Q3 FY 25 © 2024 Granules India Limited 17
Slide 19: ANDA/Dossier filing status
ANDA/Dossier filing status Tentatively ANDA/Dossier filed - Therapeutic area wise Filing Status Approved Filed Total Products Approved CNS 25 GPI IP USA 30 0 3 33 Analgesics 25 Other areas 12 USA 37 1 12 50 Anti-diabetic 11 Europe 8 0 4 12 Cardiovascular 10 Anti-Inflammatory 8 GIL IP Canada 7 0 0 7
Slide 20: Sustainability at Granules
Sustainability at Granules : Pioneering Innovation for Complete Supply Chain Decarbonization of Pharmaceuticals Our SBTi Targets Approved 27.8 % Near-term, Long-term, and Net Zero targets (2050 or sooner), aligned to 1.5°C pathway, Scope1 and Scope2 have been validated and approved by SBTi Intensity
Slide 21: GHG Emission Disclosure
GHG Emission Disclosure Our emission disclosures for FY 23 has been updated during FY 24 disclosure cycle to include emissions for all our subsidiaries and now includes disclosure of our comprehensive scope 3 emissions in addition to previously disclosed Scope 1 and Scope 2 emissions. Granules scope
Slide 22: Social Impact Initiative: Pharma Pathshala at Swarna Bharat Trust
Social Impact Initiative : Pharma Pathshala at Swarna Bharat Trust Granules initiative to train a rural workforce through the Swarna Bharat Trust Earnings Presentation – Q3 FY 25 © 2024 Granules India Limited 21
Slide 23: Corporate address and investor relations contacts
For investor relation – Granules IR desk Email: investorrelations@granulesindia.com www.granulesindia.com Ms. Payal Dave payal.dave@linkintime.co.in Mr. Irfan Raeen +91 97737 78669 532482 Irfan.raeen@linkintime.co.in GRANULES www.orientcap.com GRAN:IN GRAN:NS Corporate address: Floor 2 Block 3 My Ho